annual meeting program - American Society of Clinical Oncology

8:00 AM - 12:00 PM
GENERAL POSTER SESSION
Saturday, June 5, 2010
Tumor Biology
Location: S Hall A2
Tracks(s): Tumor Biology
Brd. 40A EGFR mutations in men and cigarette smokers with lung adenocarcinoma.
(Abstract #10538)
M. Pietanza, S. P. D’Angelo, M. L. Johnson, P. K. Paik, G. J. Riely, V. A. Miller,
M. F. Zakowski, V. W. Rusch, M. Ladanyi, M. G. Kris
Brd. 40B Molecular types and prognostic markers PA/PAI-1 for 2,497 early breast
cancer patients in the multicenter, randomized NNBC 3-Europe trial.
(Abstract #10539)
E. J. Kantelhardt, C. Thomssen, M. Vetter, C. Meisner, M. Schmidt, P. Martin,
F. Sweep, G. Von Minckwitz, M. Schmitt, N. Harbeck, on behalf of the NNBC
3-Europe Study Group
Brd. 40F Treatment of carcinoma of unknown primary site (CUP) directed by
molecular profiling diagnosis: A prospective, phase II trial. (Abstract #10540)
J. D. Hainsworth, D. R. Spigel, M. S. Rubin, R. V. Boccia, E. P. Fox, I. Firdaus,
M. G. Erlander, C. Schnabel, F. A. Greco
Brd. 40G Effect of IKK� knock-down on prostate cancer xenograft growth. (Abstract
#10541)
B. Péant, Y. Huon, K. Leclerc-Desaulniers, N. Delvoye, M. Latour, A. Mes-Masson,
F. Saad
Brd. 40H Immunohistochemistry detection of epidermal growth factor receptor (EGFR)
exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using
novel mutation specific antibodies. (Abstract #10542)
Y. Kato, N. Peled, K. Yoshida, M. W. Wynes, M. Pardo, C. J. Mascaux, M. Tsuboi,
T. Ohira, N. Ikeda, F. R. Hirsch
Brd. 41A Analysis of the methylation profile of 49 cancer-related regions in human
breast cancer. (Abstract #10543)
D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, M. Roqué, L. M. Vargas-Roig
Brd. 41B Prospective multicentric trial evaluating prognostic and predictive value of
circulating tumor cells in first-line chemotherapy metastatic breast patients.
(Abstract #10544)
J. Pierga, T. D. Bachelot, F. Bidard, S. Delaloge, E. Brain, M. Campone,
B. Asselain, C. Mathiot
Brd. 41C Effect of kinesins on taxane resistance. (Abstract #10545)
R. Wesolowski, M. Orloff, E. Downs-Kelly, G. T. Budd, G. R. Stark, S. De,
R. R. Tubbs, J. P. Crowe, C. Eng
Brd. 41D Impact of high-risk classification by FISH on overall survival in myeloma: An
Eastern Cooperative Oncology Group (ECOG) study E4A03. (Abstract
#10546)
S. J. Jacobus, S. A. Van Wier, G. J. Ahmann, K. J. Henderson, N. S. Callander,
M. E. Williams, D. S. Siegel, P. R. Greipp, S. V. Rajkumar, R. Fonseca
Brd. 41E Early operable primary breast cancer in elderly (> 70 years) women: Are they
biologically different from their younger counterparts? (Abstract #10547)
K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis
Brd. 41F Can cetuximab specific IgE antibodies predict cetuximab-induced
anaphylaxis? (Abstract #10548)
B. Dupont, D. Mariotte, M. Galais, K. Bouhier, B. Le Mauff, J. Reimund, R. Gervais
Brd. 41G Determining true HER2 status in breast cancers with polysomy using
alternative chromosome 17 reference genes: Implications for trastuzumab
therapy. (Abstract #10549)
A. M. Gown, C. C. Tse, L. C. Goldstein, P. L. Kandalaft, H. C. Hwang
107
SATURDAY